131 related articles for article (PubMed ID: 2064957)
1. Selective purging by human interleukin-2 activated lymphocytes of bone marrows contaminated with a lymphoma line or autologous leukaemic cells.
Gambacorti-Passerini C; Rivoltini L; Fizzotti M; Rodolfo M; Sensi ML; Castelli C; Orazi A; Polli N; Bregni M; Siena S
Br J Haematol; 1991 Jun; 78(2):197-205. PubMed ID: 2064957
[TBL] [Abstract][Full Text] [Related]
2. Autologous bone marrow purging by in situ IL-2 activation of endogenous killer cells.
Margolin KA; Wright C; Forman SJ
Leukemia; 1997 May; 11(5):723-8. PubMed ID: 9180298
[TBL] [Abstract][Full Text] [Related]
3. Susceptibility of human leukemia to allogeneic and autologous lymphokine-activated killer cell activity: analysis of 252 samples.
Teichmann JV; Ludwig WD; Thiel E
Nat Immun; 1992; 11(3):117-32. PubMed ID: 1392400
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxicity of interleukin 2-activated lymphocytes for leukemia and lymphoma cells.
Oshimi K; Oshimi Y; Akutsu M; Takei Y; Saito H; Okada M; Mizoguchi H
Blood; 1986 Oct; 68(4):938-48. PubMed ID: 3489494
[TBL] [Abstract][Full Text] [Related]
5. Lymphokine-activated killer (LAK) cells and cytokines synergize to kill clonal cells in acute myeloid leukemia (AML) in vitro.
Braun S; Gerhartz HH; Schmetzer HM
Haematologia (Budap); 2000; 30(4):271-88. PubMed ID: 11204027
[TBL] [Abstract][Full Text] [Related]
6. Lymphokine-activated killer (LAK) cell purging of bone marrow.
Cramer DV; Long GS
Prog Clin Biol Res; 1990; 333():125-35; discussion 136-7. PubMed ID: 2308977
[TBL] [Abstract][Full Text] [Related]
7. Effects of cancer immunotherapy with indomethacin and interleukin-2 on murine hemopoietic stem cells.
Saarloos MN; Khoo NK; Lala PK
Cancer Res; 1992 Dec; 52(23):6452-62. PubMed ID: 1423293
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of lymphokine-activated killer cells generated from bone marrow mononuclear cells for the purging of residual tumor cells in peripheral blood stem cell graft.
Komatsu F; Kajiwara M
Jpn J Cancer Res; 1996 Feb; 87(2):161-9. PubMed ID: 8609065
[TBL] [Abstract][Full Text] [Related]
9. Induction by interleukin-7 of lymphokine-activated killer activity in lymphocytes from autologous and syngeneic marrow transplant recipients before and after systemic interleukin-2 therapy.
Pavletic Z; Benyunes MC; Thompson JA; Lindgren CG; Massumoto C; Alderson MR; Buckner CD; Fefer A
Exp Hematol; 1993 Sep; 21(10):1371-8. PubMed ID: 8359237
[TBL] [Abstract][Full Text] [Related]
10. Lymphokine-activated killer function following autologous bone marrow transplantation for refractory hematological malignancies.
Higuchi CM; Thompson JA; Cox T; Lindgren CG; Buckner CD; Fefer A
Cancer Res; 1989 Oct; 49(20):5509-13. PubMed ID: 2477142
[TBL] [Abstract][Full Text] [Related]
11. Lymphokine-activated killer cell purging of leukemia cells from bone marrow prior to syngeneic transplantation.
Long GS; Hiserodt JC; Harnaha JB; Cramer DV
Transplantation; 1988 Sep; 46(3):433-8. PubMed ID: 2901797
[TBL] [Abstract][Full Text] [Related]
12. Influence of cytokines and autologous lymphokine-activated killer cells on leukemic bone marrow cells and colonies in AML.
Braun SW; Gerhartz HH; Schmetzer HM
Acta Haematol; 2001; 105(4):209-21. PubMed ID: 11528095
[TBL] [Abstract][Full Text] [Related]
13. Combination of interleukin-2-stimulated lymphocytes and bispecific antibodies that efficiently lyse leukemic cells does not affect bone marrow CD34-positive stem cell function in vitro.
Kaneko T; Fukuda J; Teramura M; Fusauchi Y; Kakui Y; Okumura K; Mizoguchi H; Oshimi K
Bone Marrow Transplant; 1994 Aug; 14(2):213-7. PubMed ID: 7527685
[TBL] [Abstract][Full Text] [Related]
14. Lymphokine-activated killer cells selectively kill tumor cells in bone marrow without compromising bone marrow stem cell function in vitro.
van den Brink MR; Voogt PJ; Marijt WA; van Luxemburg-Heys SA; van Rood JJ; Brand A
Blood; 1989 Jul; 74(1):354-60. PubMed ID: 2787676
[TBL] [Abstract][Full Text] [Related]
15. LAK-cell-mediated cytotoxicity against tumor cell targets used to monitor the stimulatory effect of interleukin-2: cytotoxicity, target recognition and phenotype of effector cells lysing the Daudi, T24 and K562 tumor cell lines.
Hermann GG; Zeuthen J; Claësson MH
Nat Immun; 1992; 11(1):7-16. PubMed ID: 1611282
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients: II. Feasibility of LAK generation in children with active disease and in remission.
Adler A; Albo V; Blatt J; Whiteside TL; Herberman RB
Blood; 1989 Oct; 74(5):1690-7. PubMed ID: 2790193
[TBL] [Abstract][Full Text] [Related]
17. Use of a lethally irradiated major histocompatibility complex nonrestricted cytotoxic T-cell line for effective purging of marrows containing lysis-sensitive or -resistant leukemic targets.
Cesano A; Pierson G; Visonneau S; Migliaccio AR; Santoli D
Blood; 1996 Jan; 87(1):393-403. PubMed ID: 8547668
[TBL] [Abstract][Full Text] [Related]
18. Lymphokine-activated killer (LAK) cells discriminate between Epstein-Barr virus (EBV)-positive Burkitt's lymphoma cells.
Misko IS; Schmidt C; Martin N; Moss DJ; Sculley TB; Burrows S; Burman KJ
Int J Cancer; 1990 Sep; 46(3):399-404. PubMed ID: 2168343
[TBL] [Abstract][Full Text] [Related]
19. Generation of lymphokine-activated killer (LAK) cells and possible implications in autologous bone marrow transplantation--a preliminary report.
Tzeng CH; Chuang MW; Wang SY; Hsieh RK; Liu CJ; Fan S; Chen PM
Proc Natl Sci Counc Repub China B; 1990 Jan; 14(1):47-53. PubMed ID: 2381997
[TBL] [Abstract][Full Text] [Related]
20. [Experimental study of LAK and activated NK cells affecting hematopoiesis in mice].
Sun K; Zhang M; Tian Z
Zhonghua Xue Ye Xue Za Zhi; 1999 Aug; 20(8):405-8. PubMed ID: 11721419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
